Current Edition

Ilaris

Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failure

Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be …

Continue Reading →
immunotherapy

Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?

Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But …

Continue Reading →